SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of 32nd Annual General Meeting05-08-2024
05-08-2024
Taro integration underway, no major structural changes, says Sun Pharma CMD
Sun Pharma's netprofitfor the period under review stood at 2,835 crore, up 40.2 per cent over the same period last year02-08-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding Loss of Share Certificate02-08-2024
Sun Pharmaceutical Industries Results Earnings Call for Q1FY25
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.01-08-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Investor Call Audio Recording
Q1FY25 - Investor Call audio recording01-08-2024
Q1FY25 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Pharmaceuticals company Sun Pharmaceutical Industries announced Q1FY25 results: Gross sales at Rs 1,25,245 million, growth of 6.3% India Formulation sales at Rs 41,445 million, up 16.4% US Formulation sales at USD 466 million, lower by 1.0% Global Specialty sales at USD 266 million, up 14.7% Global Specialty sales accounted for 17.7% of Q1FY25 sales Emerging Markets Formulation sales at USD 284 million, up by 8.8% Rest of World Formulation sales at USD 190 million, down by 2.9% R&D; investments at Rs 7,940 million compared to Rs 6,796 million for Q1FY24 EBITDA at Rs 36,076 million (including other operating revenues), up 8.3%. EBITDA margin for Q1 at 28.5% vs 27.9% during Q1FY24. Net profit for Q1FY25 was Rs 28,356 million, up 40.2% YoY; up 20.9% over adjusted net profit of Q1FY24. Dilip Shanghvi, Chairman and Managing Director of the Company said, “Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe and the completion of acquisition of Taro minority shares. These steps advance our innovative as well as generic business offerings, and will help us serve patients better.” Result PDF01-08-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Unaudited Financial Results For Q1 Of FY 2024-25
Outcome of Board Meeting01-08-2024
Sun Pharma Q1 Preview: R&D spends to hit margins; profits may rise 10%
Brokerages expect a satisfactory quarter for Sun Pharma giant with a steady growth in the topline as well as bottomline on a year-on-year (YoY) basis, however, sequentially the bottomline may get hit30-07-2024
Sun Pharma hits all time high on US FDA nod for alopecia drug 'Leqselvi'
This came after Sun Pharmaceuticals announced that the US Food and Drug Administration (USFDA) has approved its new drug application for Deuruxolitinib, a new treatment for Alopecia Areata26-07-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Intimation regarding press release26-07-2024